1. Neurath, MF . Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol 2017; 14: 269–278.
Google Scholar | Crossref | Medline | ISI2. Abou Khalil, M, Boutros, M, Nedjar, H, et al. Incidence rates and predictors of colectomy for ulcerative colitis in the era of biologics: results from a provincial database. J Gastrointest Surg 2018; 22: 124–132.
Google Scholar | Crossref | Medline3. Bernstein, CN, Ng, SC, Lakatos, PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19: 2001–2010.
Google Scholar | Medline4. Shen, B, Lashner, BA. Diagnosis and treatment of pouchitis. Gastroenterol Hepatol 2008; 4: 355–361.
Google Scholar5. Tekkis, PP, Lovegrove, RE, Tilney, HS, et al. Long-term failure and function after restorative proctocolectomy – a multi-centre study of patients from the UK National Ileal Pouch Registry. Colorectal Dis 2010; 12: 433–441.
Google Scholar | Crossref | Medline6. Fazio, VW, Kiran, RP, Remzi, FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg 2013; 257: 679–685.
Google Scholar | Crossref | Medline7. Hata, K, Ishihara, S, Nozawa, H, et al. Pouchitis after ileal pouch-anal anastomosis in ulcerative colitis: diagnosis, management, risk factors, and incidence. Dig Endosc 2017; 29: 26–34.
Google Scholar | Crossref | Medline | ISI8. de Silva, HJ, Millard, PR, Soper, N, et al. Effects of the faecal stream and stasis on the ileal pouch mucosa. Gut 1991; 32: 1166–1169.
Google Scholar | Crossref | Medline9. Shepherd, NA, Jass, JR, Duval, I, et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987; 40: 601–607.
Google Scholar | Crossref | Medline10. Schieffer, KM, Williams, ED, Yochum, GS, et al. Review article: the pathogenesis of pouchitis. Aliment Pharmacol Ther 2016; 44: 817–835.
Google Scholar | Crossref | Medline11. Smith, FM, Coffey, JC, Kell, MR, et al. A characterization of anaerobic colonization and associated mucosal adaptations in the undiseased ileal pouch. Colorectal Dis 2005; 7: 563–570.
Google Scholar | Crossref | Medline12. Young, VB, Raffals, LH, Huse, SM, et al. Multiphasic analysis of the temporal development of the distal gut microbiota in patients following ileal pouch anal anastomosis. Microbiome 2013; 1: 9.
Google Scholar | Crossref | Medline13. Kohyama, A, Ogawa, H, Funayama, Y, et al. Bacterial population moves toward a colon-like community in the pouch after total proctocolectomy. Surgery 2009; 145: 435–447.
Google Scholar | Crossref | Medline14. Shen, B, Achkar, JP, Lashner, BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301–305.
Google Scholar | Crossref | Medline | ISI15. Isaacs, KL, Sandler, RS, Abreu, M, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2007; 13: 1250–1255.
Google Scholar | Crossref | Medline | ISI16. Magro, F, Gionchetti, P, Eliakim, R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis 2017; 11: 649–670.
Google Scholar | Crossref | Medline17. Shen, B, Remzi, FH, Lavery, IC, et al. Administration of adalimumab in the treatment of Crohn’s disease of the ileal pouch. Aliment Pharmacol Ther 2009; 29: 519–526.
Google Scholar | Crossref | Medline18. Colombel, J-F, Ricart, E, Loftus, EV, et al. Management of Crohn’s disease of the ileoanal pouch with infliximab. Am J Gastroenterol 2003; 98: 2239–2244.
Google Scholar | Crossref | Medline | ISI19. Feagan, BG, Rutgeerts, P, Sands, BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699–710.
Google Scholar | Crossref | Medline | ISI20. Sandborn, WJ, Feagan, BG, Rutgeerts, P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711–721.
Google Scholar | Crossref | Medline | ISI21. Zundler, S, Becker, E, Schulze, LL, et al. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut 2019; 68: 1688–1700.
Google Scholar | Crossref | Medline22. Sedano, R, Ma, C, Pai, RK, et al. An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Aliment Pharmacol Ther 2021; 53: 1108–1117.
Google Scholar | Medline23. Gregory, M, Weaver, KN, Hoversten, P, et al. Efficacy of vedolizumab for refractory pouchitis of the ileo-anal pouch: results from a Multicenter US Cohort. Inflamm Bowel Dis 2019; 25: 1569–1576.
Google Scholar | Crossref | Medline24. Verstockt, B, Claeys, C, De Hertogh, G, et al. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: a retrospective single-centre experience. United European Gastroenterol J 2019; 7: 1215–1225.
Google Scholar | SAGE Journals | ISI25. Bär, F, Kühbacher, T, Dietrich, NA, et al. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis. Aliment Pharmacol Ther 2018; 47: 581–587.
Google Scholar | Crossref | Medline26. Singh, A, Khan, F, Lopez, R, et al. Vedolizumab for chronic antibiotic-refractory pouchitis. Gastroenterol Rep 2019; 7: 121–126.
Google Scholar | Crossref27. Mir, F, Yousef, MH, Partyka, EK, et al. Successful treatment of chronic refractory pouchitis with vedolizumab. Int J Colorectal Dis 2017; 32: 1517–1518.
Google Scholar | Crossref | Medline28. Orfanoudaki, E, Foteinogiannopoulou, K, Koutroubakis, IE. Use of vedolizumab in a patient with chronic and refractory pouchitis. Ann Gastroenterol 2018; 31: 379.
Google Scholar | Medline29. Schmid, M, Frick, J-S, Malek, N, et al. Successful treatment of pouchitis with vedolizumab, but not fecal microbiota transfer (FMT), after proctocolectomy in ulcerative colitis. Int J Colorectal Dis 2017; 32: 597–598.
Google Scholar | Crossref | Medline30. Cakir, OO . Effectiveness of vedolizumab treatment in two different anti-tumor necrosis factor alpha refractory pouchitis: a case report. World J Clin Cases 2019; 7: 2316–2321.
Google Scholar | Crossref | Medline31. Sandborn, WJ, Tremaine, WJ, Batts, KP, et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994; 69: 409–415.
Google Scholar | Crossref | Medline | ISI32. von Elm, E, Altman, DG, Egger, M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453–1457.
Google Scholar | Crossref | Medline | ISI33. Zundler, S, Fischer, A, Schillinger, D, et al. The α4β1 homing pathway is essential for ileal homing of Crohn’s disease effector T cells in vivo. Inflamm Bowel Dis 2017; 23: 379–391.
Google Scholar | Crossref | Medline | ISI34. Binder, M-T, Becker, E, Wiendl, M, et al. Similar inhibition of dynamic adhesion of lymphocytes from IBD patients to MAdCAM-1 by vedolizumab and etrolizumab-s. Inflamm Bowel Dis 2018; 24: 1237–1250.
Google Scholar | Crossref | Medline35. Schweighoffer, T, Tanaka, Y, Tidswell, M, et al. Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism. J Immunol 1993; 151: 717–729.
Google Scholar | Medline | ISI36. Iwata, M, Hirakiyama, A, Eshima, Y, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 2004; 21: 527–538.
Google Scholar | Crossref | Medline | ISI37. Berlin, C, Berg, EL, Briskin, MJ, et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185–195.
Google Scholar | Crossref | Medline | ISI38. Briskin, M, Winsor-Hines, D, Shyjan, A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97–110.
Google Scholar | Medline | ISI39. Hesterberg, PE, Winsor-Hines, D, Briskin, MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996; 111: 1373–1380.
Google Scholar | Crossref | Medline | ISI40. Parikh, A, Leach, T, Wyant, T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis 2012; 18: 1470–1479.
Google Scholar | Crossref | Medline | ISI41. Amiot, A, Serrero, M, Peyrin-Biroulet, L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther 2017; 46: 310–321.
Google Scholar | Crossref | Medline42. Dulai, PS, Singh, S, Jiang, X, et al. The real-world effectiveness and safety of vedolizumab for moderate–severe Crohn’s disease: results from the US VICTORY Consortium. Am J Gastroenterol 2016; 111: 1147–1155.
Google Scholar | Crossref | Medline43. Zundler, S, Klingberg, A, Schillinger, D, et al. Three-dimensional cross-sectional light-sheet microscopy imaging of the inflamed mouse gut. Gastroenterology 2017; 153: 898–900.
Google Scholar | Crossref | Medline44. Thomas, PD, Forbes, A, Price, AB, et al. Differential expression of cell adhesion molecules within inflamed ileal pouch mucosa: relationship to recruited cell subtypes. Eur J Gastroenterol Hepatol 2002; 14: 137–144.
Google Scholar | Crossref | Medline45. de Krijger, M, Wildenberg, ME, Mookhoek, A, et al. Expression of MAdCAM-1 and gut-homing T-cells in inflamed pouch mucosa. J Crohns Colitis 2021; 15: 1491–1499.
Google Scholar | Crossref | Medline46. Fischer, A, Zundler, S, Atreya, R, et al. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 2016; 65: 1642–1664.
Google Scholar | Crossref | Medline47. Atlantic Pharmaceuticals Ltd . A randomized, double-blind, placebo-controlled trial of the safety and efficacy of topical alicaforsen enema in subjects with active, chronic, antibiotic refractory primary idiopathic pouchitis. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/results/NCT02525523 (2020, accessed 11 April 2021).
Google Scholar48. Allner, C, Melde, M, Becker, E, et al. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020; 20: 103.